CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that pre-clinical data will be presented that supports CAT-2054 as a potential treatment for NASH at Digestive Disease Week 2016 held May 21 - 24, 2016, in San Diego, California at the San Diego Convention Center. The data that will be presented was generated using CAT-2003, an analog of CAT-2054, to demonstrate the potential of CAT-2054 in NASH. CAT-2054 is currently in a Phase 2a clinical trial in patients with hypercholesterolemia.
